Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma

Dr. Reddy's announces the first-to-market, OTC launch of Allegra-D in the US market

Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.

Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA

ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.

Piramal Pharma strengthens board by inducting three new board members

The appointments will add to the well-diversified experience that currently exists on the PPL board.

Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma

Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.

Dr. Reddy's Lab launches sorafenib tablets in US

Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.

CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics

The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics

ANI Pharmaceuticals consolidates operation post Novitium acquisition

Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023

Indian pharma market to grow at a CAGR of 12.3% to US$130 bn

PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030

Bempedoic acid market in India will get crowded soon: GlobalData

Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe